GLP1

Apr 28, 2026

FYI: Your old diet program added Foundayo eight days after approval. The 12-month contract didn't change.

WeightWatchers filed for bankruptcy in May 2025. It came back as a telehealth platform that prescribes Ozempic, Wegovy, Zepbound, and now Foundayo. Its board includes the man who launched Mounjaro for Eli Lilly. The CEO who built the pivot left last month. The 12-month subscription contract that comes with all of it has not moved.

Apr 26, 2026

FYI: The same drug. Four cost-effectiveness studies. Four wildly different answers.

Yesterday Off Label introduced Dr. David Kim. Today we teach you to read his papers (and any cost-effectiveness study) the way the policy world reads them. The same drug. Four studies. Four wildly different answers. Six things to check. Once you can do this, you stop being intimidated by citations and start being able to push back on insurance denials with the right framing.

Apr 25, 2026

FYI: Meet the UChicago researcher whose math just predicted the federal GLP-1 retreat. (4 days early.)

Dr. David Kim cold-emailed Harvard as a student. He's now a UChicago health economist whose three peer-reviewed papers built the academic case that GLP-1s aren't cost-effective at lifetime use prices. The federal government walked away from Medicare Part D expansion 4 days ago. Kim's framework just got validated in real time.

Apr 24, 2026

FYI: The "lifetime use" framing is drug company spin. (And the science is starting to push back.)

Why "you have to take this forever" is positioning, not consensus. UK NICE has a 2-year cap. Real-world data shows fewer than 1 in 4 patients stay on a GLP-1 after 1 year. The cost-effectiveness studies say current prices fail at lifetime use. The federal government just delayed Medicare expansion. The evidence is shifting. The marketing hasn't.

Apr 24, 2026

FYI: How to actually stop a GLP-1 without losing the progress.

The evidence-based playbook for stopping a GLP-1 without the 60% average weight regain. Slow taper. Protein floor. Generic bridge meds. Clear restart triggers. The protocol based on the newest 2026 data your doctor may not have walked you through.

Apr 24, 2026

FYI: The GLP-1 off-ramp just got real. A new procedure might solve weight regain.

A 45-patient trial shows a one-time endoscopic procedure prevents post-GLP-1 weight regain. Plus why it's not available for you yet, and the stock that's betting everything on the Q4 pivotal readout.

Apr 24, 2026

FYI: Your GLP-1 fears, answered.

FDA warning letter March 5. 68.6x vision risk. 15-40% muscle loss range. Real dangers vs social media panic. Answering 8 reader questions with actual data.

Apr 24, 2026

FYI: GLP-1s are quietly rewriting romance and work in America. Here's the facts.

Bariatric divorce is a real phrase now. 34% of US employers cover these drugs. Dating app matches are spiking. Here's the culture report nobody else is writing.

GLP1

FYI: Your old diet program added Foundayo eight days after approval. The 12-month contract didn't change.

FYI: The same drug. Four cost-effectiveness studies. Four wildly different answers.

FYI: Meet the UChicago researcher whose math just predicted the federal GLP-1 retreat. (4 days early.)

FYI: The "lifetime use" framing is drug company spin. (And the science is starting to push back.)

FYI: How to actually stop a GLP-1 without losing the progress.

FYI: The GLP-1 off-ramp just got real. A new procedure might solve weight regain.

FYI: Your GLP-1 fears, answered.

FYI: GLP-1s are quietly rewriting romance and work in America. Here's the facts.

Quick Links

Subscription

Socials